Company: MYGN
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000899923-25-000019
Chunk: 141

Company: MYRIAD GENETICS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 141
---
.5)(10.3)Inventory(6.2)(1.8)(2.9)Prepaid taxes0.5 0.7 0.7 Other assets— 0.6 (0.9)Tenant improvement allowance received— 16.3 18.0 Accounts payable4.7 (3.7)(3.5)Accrued liabilities(41.0)27.2 (86.2)Net cash used in operating activities(8.7)(110.9)(106.3)CASH FLOWS FROM INVESTING ACTIVITIES:Capital expenditures(19.0)(63.2)(45.3)Capitalization of internal-use software costs(10.7)(10.1)— Proceeds from the sale of business, net cash sold8.8 — — Acquisitions, net of cash acquired— — (57.2)Purchases of marketable investment securities— — (103.2)Proceeds from maturities and sales of marketable investment securities9.0 105.2 128.2 Net cash provided by (used in) investing activities(11.9)31.9 (77.5)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from common stock issued under stock-based compensation plans5.9 6.0 6.3 Payment of contingent consideration recognized at acquisition— — (3.0)Payment of tax withheld for common stock issued under stock-based compensation plans(13.4)(8.8)(10.6)Proceeds from underwritten public offering, net of costs and discounts— 117.6 — Proceeds from revolving credit facility120.0 80.0 — Repayment of revolving credit facility(119.5)(40.0)— Fees associated with issuance and refinancing of revolving credit facility— (1.7)(0.7)Payment on finance leases(0.4)(0.2)— Net cash provided by (used in) financing activities(7.4)152.9 (8.0)Effect of foreign exchange rates on cash, cash equivalents, and restricted cash(1.0)0.6 (0.6)Net increase (decrease) in cash, cash equivalents, and restricted cash(29.0)74.5 (192.4)Cash, cash